Camberlogo (Camberlogo)
Eslicarbazepine Acetate Tablet
Product Images NDC 31722-429
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Eslicarbazepine Acetate (NDC 31722-429). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Camberlogo2 (Camberlogo2)
Eslicarbazepine-tablets-200mg-30s-container (Eslicarbazepine Tablets 200mg 30s Container)
Eslicarbazepine Acetate Tablets 200 mg oral tablets label from Camber Pharmaceuticals, Inc. The label indicates a 30-tablet quantity with instructions for pharmacist dispensing and storage conditions. It includes an NDC code 31722-428-30, a barcode, and manufacturer details for Camber Pharmaceuticals and Hetero Labs Limited, India.*
Eslicarbazepine-tablets-400mg-30s-container (Eslicarbazepine Tablets 400mg 30s Container)
Label for Eslicarbazepine Acetate Tablets 400 mg oral tablets by Camber Pharmaceuticals, Inc. The label indicates once daily use, contains 30 tablets, and includes storage instructions between 20°C to 25°C. It also provides the U.S. contact number and manufacturer details, including Hetero Labs Limited in India. The NDC number is 31722-429-30.*
Eslicarbazepine-tablets-600mg-60s-container (Eslicarbazepine Tablets 600mg 60s Container)
Label for Eslicarbazepine Acetate Tablets 600 mg by Camber Pharmaceuticals, Inc. The oral tablet package contains 60 tablets. The label includes storage instructions, a barcode, and manufacturer information. The product is for prescription use only with a pharmacist note to dispense the accompanying medication guide.*
Eslicarbazepine-tablets-600mg-90s-container (Eslicarbazepine Tablets 600mg 90s Container)
Label for Eslicarbazepine Acetate Tablets 600 mg oral tablets by Camber Pharmaceuticals, Inc. The label indicates a 90-tablet package with a once-daily dosage. It includes storage instructions, pharmacist dispensing guidance, a barcode, manufacturer and distributor details, and contact information.*
Eslicarbazepine-tablets-800mg-30s-container (Eslicarbazepine Tablets 800mg 30s Container)
Label for Eslicarbazepine Acetate Tablets 800 mg oral tablet, containing 30 tablets per package. Manufactured for Camber Pharmaceuticals, Inc. The label includes dosage storage instructions, pharmacy dispensing guidance, and a barcode. The product is designated Rx only and includes contact information for the U.S.*
Eslicarbazepine-tablets-800mg-90s-container (Eslicarbazepine Tablets 800mg 90s Container)
Label for Eslicarbazepine Acetate Tablets 800 mg oral tablets by Camber Pharmaceuticals, Inc. The label states the strength as 800 mg, package includes 90 tablets, and emphasizes once daily dosing. Storage instructions and contact information for the U.S. are provided. Manufactured for Camber Pharmaceuticals in New Jersey, with production by Hetero Labs Limited in India.*
Eslicarbazipinetabletsfigure1 (Eslicarbazipinetabletsfigure1)
A plot depicting fold change and 90% confidence interval of eslicarbazepine acetate exposure changes along the vertical axis by different patient factors, including age (≥65 years), gender (female), hepatic impairment (mild, moderate, severe), and renal impairment (mild, moderate, severe). Recommendations for dose adjustments based on these conditions are noted on the right side of the chart.*
Eslicarbazipinetabletsfigure2 (Eslicarbazipinetabletsfigure2)
A forest plot chart showing the fold change and 90% confidence interval for eslicarbazepine acetate relative to different drugs, with recommendations on dose adjustments. Drugs listed include Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate, with some recommendations indicating potential need for dose adjustments of eslicarbazepine acetate.*
Eslicarbazipinetabletsfigure3 (Eslicarbazipinetabletsfigure3)
A chart depicting fold change and 90% confidence intervals for various antiepileptic drugs (AEDs) including Carbamazepine, Gabapentin, Lamotrigine, Levetiracetam, Phenobarbital, Phenytoin, Topiramate, and Valproate. The chart includes recommendations for dose adjustments or monitoring, such as dose adjustment for Carbamazepine and phenytoin concentration monitoring. The horizontal axis represents the change in other drugs relative to a reference.*
Eslicarbazipinetabletsfigure4 (Eslicarbazipinetabletsfigure4)
A chart illustrating fold change and 90% confidence intervals for various drugs relative to a reference, alongside recommendations. It includes non-AEDs such as digoxin and metformin, statins like simvastatin and rosuvastatin, oral contraceptives including ethinylestradiol and levonorgestrel, and warfarin forms (S- and R-warfarin). The chart provides dosage adjustment and monitoring recommendations based on changes in lipid levels or INR for concurrent drug use.*
Eslicarbazipinetabletsfigure5 (Eslicarbazipinetabletsfigure5)
A Kaplan-Meier (KM) estimate chart showing exit rates (%) with 95% confidence intervals for Eslicarbazepine acetate at doses of 1200 mg and 1600 mg. Data points from two studies are plotted, with sample sizes (N) indicated, comparing exit rates against historical controls represented by a dashed horizontal line.*
Eslicarbazipinetabletsfigure6 (Eslicarbazipinetabletsfigure6)
A bar chart depicting the proportion of patients (%) experiencing different levels of reduction in seizure frequency from baseline (%) comparing placebo, Eslicarbazepine acetate 800 mg, and Eslicarbazepine acetate 1200 mg groups. The x-axis shows seizure reduction ranges and the y-axis shows patient proportion percentage, illustrating relative efficacy between treatment and placebo.*
Eslicarbazipinetabletsstructure (Eslicarbazipinetabletsstructure)
Chemical structure of Eslicarbazepine acetate showing its molecular arrangement with labeled atoms and bonds.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
